UCB announced on March 8, 2022 that it will build a new innovative facility, focused on gene therapy process development and clinical manufacturing, in Wallonia, Belgium. The 17,0000-sq.-ft. facility is expected to be operational in 2024 and will provide end-to-end process and analytical development, clinical manufacturing, quality control, scalability, and speed to UCB’s gene therapy research projects. Source: Biopharm International 10/3/22